Current use of imaging after primary treatment of prostate cancer

Ahmed A. Hussein, Sanoj Punnen, Shoujun Zhao, Janet E. Cowan, Michael Leapman, Thanh C. Tran, Samuel L. Washington, Matthew D. Truesdale, Peter R. Carroll, Matthew R. Cooperberg

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose Data are limited on imaging after primary treatment of localized prostate cancer. Materials and Methods We identified 8,435 men newly diagnosed with nonmetastatic prostate cancer in 1995 to 2012 who were enrolled in CaPSURE™. Patients were followed after primary treatment with radical prostatectomy, cryosurgery, brachytherapy, external beam radiation therapy or androgen deprivation therapy. We assessed the use of bone scan, computerized tomography and magnetic resonance imaging after primary treatment. Factors associated with posttreatment outcomes (number of imaging tests, and time to first imaging and salvage treatment) were evaluated with multivariate Poisson regression and Cox proportional hazards regression. Results The incidence of posttreatment bone scan, computerized tomography and magnetic resonance imaging was 20% or less. Last posttreatment log(prostate specific antigen) was associated with multiple posttreatment imaging. Management by radical prostatectomy, cryosurgery, external beam radiation therapy or brachytherapy vs androgen deprivation therapy was associated with a lower likelihood of posttreatment imaging. Of patients who were imaged after treatment 25% with radical prostatectomy and 9% with radiation underwent imaging before prostate specific antigen failure. The 5-year salvage treatment-free survival rate was 81%. Positive findings on posttreatment imaging were associated with a higher risk of salvage treatment. Conclusions Patients treated with androgen deprivation therapy for localized disease were most likely to be imaged, primarily by bone scan. Men treated with other therapies were less likely to be imaged and tended to undergo computerized tomography. Imaging may add value to posttreatment prostate specific antigen monitoring to identify disease recurrence and progression. Further studies are needed to establish guidelines for the optimal frequency and imaging type to monitor the treatment response.

Original languageEnglish (US)
Pages (from-to)98-104
Number of pages7
JournalJournal of Urology
Issue number1
StatePublished - 2015
Externally publishedYes


  • diagnostic imaging
  • disease progression
  • prostate-specific antigen
  • prostatic neoplasms
  • salvage therapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Current use of imaging after primary treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this